Compare · AYTU vs SUPN
AYTU vs SUPN
Side-by-side comparison of Aytu BioPharma Inc. (AYTU) and Supernus Inc. (SUPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYTU and SUPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SUPN is the larger of the two at $6.03B, about 208.7x AYTU ($28.9M).
- SUPN has been more active in the news (36 items in the past 4 weeks vs 11 for AYTU).
- SUPN has more recent analyst coverage (9 ratings vs 3 for AYTU).
- Company
- Aytu BioPharma Inc.
- Supernus Inc.
- Price
- -
- -
- Market cap
- $28.9M
- $6.03B
- 1M return
- -
- -14.15%
- 1Y return
- -
- -7.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2012
- News (4w)
- 11
- 36
- Recent ratings
- 3
- 9
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Supernus Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.
Latest AYTU
- Aytu BioScience downgraded by Lake Street with a new price target
- SEC Form 10-Q filed by Aytu BioPharma Inc.
- SEC Form 425 filed by Aytu BioPharma Inc.
- Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
- Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
- Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
- Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
- FDA Approval for ZOLPIMIST issued to AYTU
Latest SUPN
- Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
- BofA Securities initiated coverage on Supernus Pharma with a new price target
- Director Gemayel Georges disposed of 27,277 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, Commercial Operations Horich William Todd disposed of 115,125 restricted stock units, disposed of 8,500 performance share units and disposed of 140,500 employee stock options (SEC Form 4)
- President, CEO Khattar Jack A. disposed of 2,216,451 shares, closing all direct ownership in the company (SEC Form 4)
- Senior Vice-President & CFO Dec Timothy C disposed of 9,129 shares, closing all direct ownership in the company (SEC Form 4)
- Director Barlow Carrolee disposed of 27,045 shares, closing all direct ownership in the company (SEC Form 4)
- Sr. VP of IP, CSO Bhatt Padmanabh P. disposed of 18,637 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Medical Officer Rubin Jonathan disposed of 13,979 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Tech. Ops. Officer Mottola Frank disposed of 19,544 shares, closing all direct ownership in the company (SEC Form 4)